This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Acorda Drug Helps Stroke Patients Walk Better

Stocks in this article: ACOR

ARDSLEY, NY ( TheStreet) -- Acorda Therapeutics (ACOR) announced mixed results from two proof-of-concept studies Monday aimed at expanding the use of its multiple sclerosis walking drug Ampyra to include patients suffering from strokes and cerebral palsy.

In a study of 83 patients who had experienced a stroke at least six months prior to enrollment, use of twice-daily Ampyra significantly improved walking ability compared to a placebo, Acorda said in a statement. The company didn't provide detailed data on Ampyra's efficacy

Three patients reported seizures during the study. One seizure occurred in a patient treated with a placebo. The two other seizure cases involved patients on Ampyra, although one was deemed an intentional overdose and suicide attempt.

"There were clear efficacy signals in the Ampya post-stroke deficits trial and we therefore plan to proceed with a clinical development program for this indication," said Acorda CEO Ron Cohen.

There are approximately 7 million stroke survivors in the U.S., with about half having some difficulty walking, according to the company.

In a separate trial enrolling 24 patients with cerebral palsy, Ampyra "suggested potential treatment activity" related to walking ability and hand strength, Acorda said. The data are still being analyzed to determine if the results are strong enough to justify additional clinical trials.

Ampyra sales in multiple sclerosis totaled $266 million in 2012.

"The post-stroke market is clearly large and would meaningfully expand Ampyra's potential beyond the current MS opportunity," writes ISI Group analyst Mark Schoenebaum, in an email to clients Monday morning. "Ampyra is currently annualizing at about $400M in the U.S. for MS. We calculate that every $50M in additional peak U.S. sales could increase our DCF by around $4-5 (assuming 2027 US patent expiry)."

Acorda shares were up 9% to $34.24 in Monday pre-market trading.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs